Not yet recruiting
Deutenzalutamide and Hormone Therapy Before and After Surgery With Docetaxel Before Surgery for High-Risk Localized or Locally Advanced Prostate Cancer
NCT07907653· Phase 2· Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University· Source
Contact: Wen Dong
Not yet recruiting
Arsenic Trioxide Combined With Chemotherapy for Relapsed SHH-Activated and/or TP53-Mutant Medulloblastoma
NCT07856069· Phase 2· Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University· Source
Contact: Yang Li, MD, PhD
Recruiting
MRG003 Added to Ongoing Treatment After Progression in EGFR-Positive Advanced Thyroid Cancer
NCT07874321· Phase 2· Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University· Source
Contact: Tianrun Liu
Recruiting
Adebrelimab Combined With Neoadjuvant Chemoradiotherapy for Esophageal Squamous Cell Carcinoma
NCT07595770· Phase 2· Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University· Source
Contact: Baisheng Chen Chen
Recruiting
A Study to Evaluate the Effectiveness and Safety of Setidegrasib, Given With Either mFOLFIRINOX or NALIRIFOX Chemotherapies, in People With Pancreatic Cancer
NCT07409272· Phase 3· Astellas Pharma Global Development, Inc.· Source
Contact: Astellas Pharma Global Development, Inc.
Recruiting
Large Language Models Assist in Tumor MDT
NCT07504367· Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University· Source
Contact: Herui Yao, PhD
Not yet recruiting
Development and Prospective Validation of a Pathology-Based Artificial Intelligence Model for Predicting the Time to Castration Resistance of Prostate Cancer
NCT07376057· Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University· Source
Contact: Cuimei Yao
Recruiting
Phase II Study of Trastuzumab Rezetecan or in Combination With Adebrelimab in HER2-Expressing Locally Advanced or Metastatic Urothelial Carcinoma (la/mUC)
NCT07241793· Phase 2· Sun Yat-sen University· Source
Contact: Tao Qin, Doctor
Recruiting
BDB-001 Phase III Trial in ANCA-Associated Vasculitis
NCT07168161· Phase 3· Staidson (Beijing) Biopharmaceuticals Co., Ltd· Source
Contact: Lie Dai
Recruiting
Evaluation of the Safety and Effectiveness of CHORDS® Cerebral Protection System During TAVR: DUET Trial
NCT07648693· Resonova (Shanghai) Medtech Limited· Source
Contact: Zou Yanqin
Recruiting
Camrelizumab and Apatinib With or Without FOLFOX Chemotherapy for Advanced HCC
NCT07267806· Phase 3· Linhui Peng· Source
Contact: Linhui Peng
Recruiting
Guiding Value of Urinary Tumor DNA Testing in Repeat Transurethral Resection of Non-Muscle-Invasive Bladder Cancer
NCT07187635· Tianjin Medical University Second Hospital· Source
Contact: Xu Chen
Not yet recruiting
A Study of Sacituzumab Govitecan Plus Toripalimab Versus Toripalimab Plus Nab-Paclitaxel in PD-L1 Positive Advanced TNBC
NCT07040644· Phase 2· Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University· Source
Contact: Sun Yat-sen Memorial Hospital of Sun Yat-sen University
Not yet recruiting
Comparing Endocrine Therapy Combined With High-Dose Palbociclib and Hydroxychloroquine to Endocrine Therapy Combined With Standard-Dose Palbociclib for Hormone Receptor-Positive and HER2-Negative Advanced Breast Cancer
NCT07061717· Phase 3· Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University· Source
Contact: Chang Gong
Recruiting
Efficacy and Safety of rTMS Combined With HA in the Treatment of Cognitive Decline in Aged Related Hearing Loss
NCT07389213· Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University· Source
Contact: Haidi Yang, PhD
Recruiting
Anlotinib + Benmelstobart + HAIC in Unresectable HCC: A Phase II Study
NCT07806292· Phase 2· Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University· Source
Contact: Changzhen Shang
Recruiting
A Trial of Apatinib and Adebrelimab in Combination With Chemotherapy in Patients With Unresectable ICC
NCT06925516· Phase 2· Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University· Source
Contact: Changzhen Shang, M.D, PhD
Enrolling by invitation
Catheter Ablation for Functional Mitral Regurgitation in Persistent Atrial Fibrillation: Development and Validation of a Predictive Model-A Multicenter Prospective Cohort Study
NCT07096219· Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University· Source
Recruiting
Long-term Follow-up Study of BRL-101 for TDT
NCT06298630· Bioray Laboratories· Source
Contact: Jianpei Fang, phD
Recruiting
Comparing the Efficacy of Domestic Versus Imported Hearing Aids in ARHL
NCT06882889· Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University· Source
Contact: Haidi Yang, PhD
Active, not recruiting
Study of Sacituzumab Govitecan Versus Treatment of Physician's Choice in Participants With Endometrial Cancer After Platinum-Based Chemotherapy and Immunotherapy (ASCENT-GYN-01/GOG-3104/ENGOT-en26)
NCT06486441· Phase 3· Gilead Sciences· Source
Recruiting
Postoperative Adjuvant Therapy of Donafenib for Hepatocellular Carcinoma
NCT06581315· Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University· Source
Contact: Changzhen Shang, MD
Recruiting
The Value of CEUS in Assessing the Response of Cervical Lymph Nodes After NACI for HNSCC
NCT06727162· Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University· Source
Contact: Lin Peiliang
Recruiting
Development and Prospective Validation of a Digital Pathology-based Artificial Intelligence Diagnostic Model for Pan-cancer Lymphatic Metastasis
NCT06517979· Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University· Source
Contact: Cuimei Yao
Recruiting
Deep Learning-based sbORN Diagnostic Model
NCT06463392· Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University· Source
Contact: Xiang-Wei Kong, Ph.D.
Recruiting
Feasibility and Safety of Robotic Assisted Proximal Gastrectomy With Double-flap Technique for Proximal Early Gastric Cancer
NCT05892289· Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University· Source
Contact: Yang bin
Recruiting
Exploratory Study on HER2 Detection Method and Positive Threshold for High-grade Serous Adenocarcinoma of the Ovary
NCT06883487· Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University· Source
Contact: Jing Li
Recruiting
Combination Immunotherapy of Adebrelimab With Apatinib and Tegafur, Gimeracil and Oteracil Potassium Capsules for Immune Rechallenge Therapy in Esophageal Squamous Cell Carcinoma
NCT06339619· Phase 2· Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University· Source
Contact: Minghui Wang, Dr.
Recruiting
Chemotherapy Combined With Adebrelimab and Apatinib as the Perioperative Treatment in Patients With Biliary Tract Cancer
NCT06280508· Phase 2· Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University· Source
Contact: Yajin Chen
Recruiting
mFOLFOX7 Plus Camrelizumab and Apatinib in BCLC Stage A/B Hepatocellular Carcinoma Patients Beyond Milan Criteria
NCT06607107· Phase 2· Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University· Source
Contact: Linhui Peng, Prof
Active, not recruiting
Neoadjuvant Pyrotinib in HR-positive and HER2-low High-risk Early Breast Cancer
NCT06144944· Phase 3· Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University· Source
Recruiting
TEER for Severe DMR of Low to Intermediate Surgery Risk
NCT06162780· Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University· Source
Contact: Yangxin Chen, PhD
Recruiting
Infusional FOLFOX Plus Camrelizumab and Apatinib vs HAIC-FOLFOX Plus Camrelizumab and Apatinib for Advanced HCC
NCT06172205· Phase 3· Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University· Source
Contact: Yunxiuxiu Xu, MD
Not yet recruiting
Laparoscopic Proximal Gastrectomy With Double-flap Technique Versus Laparoscopic Total Gastrectomy With Roux-en-Y Reconstruction for Proximal Early Gastric Cancer
NCT05890339· Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University· Source
Contact: Han Fanhai, Professor
Active, not recruiting
Study for Participants Continuing From Pfizer-sponsored Palbociclib (a Study Medicine) Studies
NCT05226871· Phase 2· Pfizer· Source
Recruiting
A Prospective Cohort Study On Change of Cognitive Function In Aged-related Hearing Loss With Hearing Aids
NCT05694039· Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University· Source
Contact: Minqian Gao, B.sc
Active, not recruiting
Tumor-informed MRD for Non-small Cell Lung Cancer
NCT07596433· Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University· Source
Active, not recruiting
Phase II Neoadjuvant Pyrotinib Combined With Neoadjuvant Chemotherapy in HER2-low-expressing and HR Positive Early or Locally Advanced Breast Cancer: a Single-arm, Non-randomized, Single-center, Open Label Trial
NCT05165225· Phase 2· Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University· Source
Recruiting
A Study of Toripalimab as Consolidation Therapy After Postoperative Chemoradiotherapy in HNSCC
NCT04992559· Phase 2· Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University· Source
Contact: Song Fan
Active, not recruiting
Asian Study of Sacituzumab Govitecan (IMMU-132) in HR+/HER2- Metastatic Breast Cancer (MBC)
NCT04639986· Phase 3· Gilead Sciences· Source